Objective. The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics.
Introduction
Infusion-related reactions (IRRs) are characterized by adverse reactions to the infusion of pharmacological or biological substances [1] . IRRs can be serious and require discontinuation of treatment. Clinical studies in RA suggested that serious infusion-related reactions (SIRRs) induced by non-TNF-targeted biologics occurred in <1% [25] . The most frequently used non-TNF-targeted biologics are abatacept (ABA), an inhibitor of T-cell co-stimulation, rituximab (RTX), a B-cell-depleting agent, and tocilizumab (TCZ), an inhibitor of the IL-6 receptor [6] . These biologics have shown their efficacy as first-line therapy. Nevertheless, in the absence of head-to-head trials, the choice is left to the clinician's discretion, and anti-TNF agents are often used as first-line treatment for the majority of patients. SIRRs after RTX, ABA and TCZ as treatment of RA in real life have not been clearly described.
The aim of the present study was to evaluate the incidence of SIRRs requiring non-TNF-targeted biologic discontinuation in three prospective French cohorts of unselected RA patients treated with RTX, ABA or TCZ.
Methods

Registries
Autoimmunity and Rituximab (AIR), Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab) (REGATE) registries are ongoing nationwide prospective cohorts focusing on the long-term safety and efficiency of i.v. RTX, ABA and TCZ, respectively, for RA treatment. AIR, ORA and REGATE registries began, respectively, in September 2005, January 2007 and April 2010. The analyses were performed on the databases on 6 March 2015. The registries and their methodologies for data collection have been described previously [79] . Briefly, standardized information about demographic, clinical and therapeutic characteristics of patients and details about IRRs, including clinical presentation, time at maximal reaction (after starting/stopping infusion), duration of the IRR and final outcome, were prospectively collected by trained clinical nurses or technicians in each centre at baseline, 3, 6 and every 6 months or at disease relapse, during 7 years for AIR and 5 years for ORA and REGATE.
In our study, the data obtained from the three registries were pooled. If a patient was included in several registries, we took into consideration the data from only the first registry. This study was approved by the Comité Consultatif sur le Traitement de l'information en matiè re de Recherche dans le domaine de la Santé and Commission Nationale de l'Informatique et des Liberté s. Informed patient consent was obtained.
Outcome
An IRR was defined by its occurrence during or within 24 h of an infusion [10] . An SIRR was defined by an IRR resulting in definitive discontinuation of treatment. Each SIRR was graded retrospectively by two investigators (J.-M.P. and J.-H.S.), who used the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and were blinded to drug treatment [11] . Disagreements were resolved by consensus. The symptoms were graded from 1 to 5 according to the CTCAE guide. An IRR was considered as grade 1 (mild) in the event of a transient flush or rash, drug fever <38 C and no requirement for intervention. A grade 2 event (moderate) was defined as symptoms requiring an intervention or interruption of infusion, a prompt improvement after symptomatic treatment (e.g. antihistamines, NSAIDs). An IRR was considered as grade 3 (severe) if the symptoms were severe, including bronchospasm with or without urticaria, allergy-related oedema/angioedema or hypotension, and required parenteral treatment. Grade 4 events were defined by life-threatening reaction with an urgent need for intervention. Grade 5 events were defined by death of the patient.
Statistical analysis
Patients contributed person-years of follow-up between first infusion and death or last follow-up visit or last infusion (in the event of discontinuation). In order to calculate the incidence rate of SIRRs, the time of the SIRR was used as the right censoring rule. By bivariable and multivariable analyses, logistic regression modelling was used to study the relationship between the outcome and other characteristics. A manual stepwise selection method was used. Poor prognosis factors and variables with a value of P < 0.10 were proposed for multivariate analysis. To avoid a confounding effect of treatment, multivariate analysis was adjusted for treatment. The bootstrap method, in which 1500 random samples were drawn, was used to assess the discriminatory power of the multivariable model, and coefficients were recalculated in each bootstrap sample. Results are expressed as the odds ratio (OR) and 95% CI. All statistical analyses were performed using SAS software release 9.4 (SAS Institute, Inc., Cary, NC, USA). A value of P < 0.05 was considered statistically significant.
Results
Study population
The AIR, ORA and REGATE registries included 1986, 1024 and 1499 patients, respectively. The median follow-up of patients was 5.9 years for RTX-treated patients The total follow-up of patients was 12 663 patient-years. Baseline characteristics of these 4145 patients with rheumatoid arthritis are summarized in Table 1 .
After data validation, SIRRs requiring treatment discontinuation occurred in 100 patients, including 56 for RTX-treated patients (2.8% or 0.7/100 patient-years), 15 for ABA (1.5% or 0.6/100 patient-years) and 29 for TCZ (1.9% or 1/ 100 patient-years) (supplementary Table S1 , available at Rheumatology Online).
Characteristics of SIRRs
An SIRR occurred after a median period of 2 [13] Table S1 , available at Rheumatology Online. There was no fatal SIRR, and all SIRRs resolved with appropriate treatment (use of antihistamines and/or CSs) and discontinuation of the infusion. A severe anaphylactic reaction was described in five patients (including two RTX during the fourth cycle, one ABA after the eighth infusion and two TCZ after the second and the fourth infusion), with a favourable outcome in all cases after treatment, including discontinuation of infusion, CS and antihistamine, with no need for use of epinephrine. Nine SIRRs (three RTX, two ABA and four TCZ) induced a prolongation of hospitalization.
Characteristics of the patients with SIRRs
Characteristics of the patients with or without SIRRs are summarized in Table 2 . Interestingly, patients with SIRRs had more often received previous anti-TNF treatment (85 vs 75.5%, P = 0.012). In patients previously treated with infliximab (INF), a previous serious infusion reaction was significantly associated with an SIRR to ABA, RTX or TCZ: 8/43 (18%) patients with SIRR and 62/1720 (3.6%) patients with no SIRR discontinued INF because of a severe reaction to INF (P = 0.001). If a patient was included in several registries, we took into consideration only the data from the first registry.
b Defined as the day of first infusion. AIR: Autoimmunity and Rituximab; ORA: Orencia (abatacept) and RA; REGATE: Registry RoAcTEmra (tocilizumab).
Compared with patients without SIRR, patients with SIRRs significantly less often received a concomitant treatment with a synthetic DMARD (52 vs 64%; P = 0.004). No significant differences were observed between patients with and without SIRR in terms of disease duration, disease activity, diabetes and other co-morbidities, as well as concomitant CS treatment.
Of note, among RTX-treated patients with SIRRs, 16/56 (28.5%) patients had at least one previous milder infusion reaction requiring interruption or a reduction in the rate of the infusion. Nineteen previous reactions occurred in 16 patients, including 3 reactions during the same cycle, 12 reactions in the previous cycle and 4 reactions at least 2 cycles before (supplementary Table S1 , available at Rheumatology Online). Among TCZ-and ABA-treated patients with SIRRs, 5/29 (17%) and 4/15 (26%) patients, respectively, presented at least one previous IRR. These IRRs occurred from 1 to 3 months before the SIRR with TCZ and between 1 and 24 months before the SIRR with ABA. Of note, all previous reactions were not serious and graded 1 or 2 (CTCAE 4.0) (supplementary Table S1 , available at Rheumatology Online).
Factors associated with SIRRs (Table 2) Multivariate analysis performed using the bootstrap method showed that positive anti-CCP was associated with a higher risk of SIRR (OR = 2.5; 95% CI: 1.01, 6.17). Absence of concomitant treatment with a synthetic DMARD tended to be associated with a higher risk of SIRR (OR = 1.67; 95% CI: 1.00, 2.86).
Discussion
To our knowledge, our study is the largest real-life prospective study of SIRRs in RA patients treated with RTX, ABA and TCZ in common practice based on national registries. The incidence of SIRRs was similar with the three treatments, although the mechanisms of action of these treatments are different.
The incidence observed in the present study is slightly higher than data from clinical trials. Indeed, previous studies reported that SIRRs occurred in 0.3% of patients treated with ABA [4], 0.2% of patients treated with TCZ [5] and <1% of patients treated with RTX [2].
The higher incidence observed in our study can be related to several points. First, the definition of SIRR is not standardized and can vary depending on the study [3, 11, 12] . We therefore chose a pragmatic approach [even though the reactions were graded CTCAE grades 15, all SIRRs described (irrespective CTCAE grading) resulted in discontinuation of treatment]. The variation of the incidence of SIRRs among the different studies can also be linked to the different methodologies used. We analysed pooled data obtained from three large and prospective French cohorts of RA patients treated with biologics. Some limitations of our study include the observational design, missing data and the absence of comparison with patients treated only with synthetic DMARDs. Last, it should be kept in mind that the present study included patients with co-morbidities who would have been excluded from controlled trials; this can also contribute to explain the fact that the present results differ from those previously described.
The majority of SIRRs were moderate (grade 1 or 2 according to CTCAE 4.0). The management of hypersensitivity reactions to biologics usually includes drug avoidance. In the case of a low-grade previous reaction, an adaptation of the infusion rate or the use of premedication may be performed. However, there is currently no official recommendation. Desensitization procedures for RTX and INF were recently described to allow the maintenance of the patient's treatment [13] .
Twenty-two SIRRs occurred after the first infusion. The pathogenesis of SIRRs occurring at first infusion is suspected to be related mainly to cytokine release syndrome [1] . SIRRs occurring after the subsequent infusions could be related to type I hypersensitivity, to complement activation [14] or to antidrug antibodies (ADAs) [1, 2, 10] . However, the role of ADAs in SIRRs is still uncertain [15, 16] . Concomitant synthetic DMARD was described as the main factor affecting development of ADAs especially to anti-TNF therapy [17] . This could explain why concomitant treatment with a synthetic DMARD, which might decrease the development of ADAs, also decreased the risk of SIRRs in the present study.
In our study, in patients previously treated with INF, a previous serious infusion reaction was significantly associated with a SIRR to RTX, ABA or TCZ. INF was not the more frequent anti-TNF used in the patients. However, when this molecule is being administered i.v. with medical surveillance, the medical team can easily note occurrence of an IRR. Moreover, a previous mild infusion reaction to RTX, ABA and TCZ was observed in a quarter of patients with a subsequent SIRR to the same drug (25/100 patients). These results suggest that a subgroup of patients exhibiting an SIRR to INF and any previous reaction to treatment could require close monitoring.
Finally, our multivariate analysis showed that a positivity for anti-CCP was associated with an increased risk of SIRR (OR = 2.5; Methods section of the supplementary data, available at Rheumatology Online). In RA patients, positivity for CCP is associated with a higher effectiveness of RTX and ABA therapy [18, 19] . However, the associations between ACPA and treatment safety have not been studied. One may speculate that the ACPA-positive patients have a global activation of the immune system and are more prone to develop an immune reaction (mediated by ADA or other mechanisms) against the biodrug. Further studies are needed to confirm our results and determine the precise underlying mechanisms of the association between anti-CCP status and SIRRs.
To conclude, the analysis of pooled results obtained from three large prospective registries of RA patients treated with RTX, ABA and TCZ showed that SIRRs are slightly more frequent in real life than in clinical trials. In addition, SIRRs are generally benign. In common practice, serological status (anti-CCP positivity) and absence of concomitant treatment with a synthetic DMARD favour the risk of serious infusion-related reactions. Prefilled syringes of TCZ and ABA have recently been commercialized. Given the rare but serious risk of SIRRs with TCZ, the French authorities recommend that the first s.c. injection be carried out in an adapted care facility. However, there is currently no recommendation for the subsequent s.c. injection of TCZ or ABA.
